Processa Pharmaceuticals, Inc. (PCSA) Operating income 2016–2025
Processa Pharmaceuticals, Inc. (PCSA) annual operating income history from SEC filings — each fiscal year as reported.
-$14.0MFY2025 · since FY2016: -$1.9M → -$14.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$14.0M | -16.1% |
| FY2024 | -$12.1M | -5.2% |
| FY2023 | -$11.5M | +58.4% |
| FY2022 | -$27.5M | -126.9% |
| FY2021 | -$12.1M | +19.8% |
| FY2020 | -$15.1M | -284.6% |
| FY2019 | -$3.9M | +13.0% |
| FY2018 | -$4.5M | -151.0% |
| FY2017 | -$1.8M | +6.2% |
| FY2016 | -$1.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PCSA financial trends
PCSA RevenuePCSA Net incomePCSA Net marginPCSA Gross profitPCSA Gross marginPCSA Operating marginPCSA Operating cash flowPCSA Free cash flowPCSA Capital expendituresPCSA Return on equityPCSA Stock buybacksPCSA Dividends paidPCSA Total assetsPCSA Total liabilitiesPCSA Shareholders’ equityPCSA overview →